Pharmacological challenge and synaptic response - Assessing dopaminergic function in the rat striatum with small animal single-photon emission computed tomography (SPECT) and positron emission tomography (PET)

Reviews in the Neurosciences

Volumn 22, Issue 6, 2011, Pages 625-645

  Nikolaus, Susanne ^a   Larisch, Rolf ^b   Vosberg, Henning ^a   Beu, Markus ^a   Wirrwar, Andreas ^c   Antke, Christina ^a   Kley, Konstantin ^d   De Souza Silva, Maria Angelica ^e   Huston, Joseph P ^e   Müller, Hans Wilhelm ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b Clinic of Nuclear Medicine   (Germany)

^c Helios Clinic Krefeld GmbH   (Germany)

^d Institute of Radiology and Nuclear Medicine   (Germany)

^e HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Dopamine D 2 receptor; Dopamine transporter; Small animal PET; Small animal SPECT

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; HALOPERIDOL; LEVODOPA; METHYLPHENIDATE; OXIDOPAMINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC TRANSMISSION; FEASIBILITY STUDY; IN VIVO STUDY; MALE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR BINDING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYNAPSE;

ADRENERGIC AGENTS; ANIMALS; BENZAMIDES; BRAIN MAPPING; CORPUS STRIATUM; DOPAMINE; DOPAMINE AGENTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MESYLATES; OXIDOPAMINE; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; PYRROLIDINES; RATS; SYNAPSES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 83655211832     PISSN: 03341763     EISSN: None     Source Type: Journal    
DOI: 10.1515/RNS.2011.054     Document Type: Article

References (158)

1. Acton, P.D., Hou, C., Kung, M.P., Plössl, K., Keeney, C.L., and Kung, H.F. (2002). Occupancy of dopamine D2 receptors in the mouse brain measured using ultra-high-resolution single-photon emission tomography and [123]IBF. Eur. J. Nucl. Med. Mol. Imaging 29, 1507-1515. (Pubitemid 35232055)
2. 11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: influence of L-dopa and lisuride therapy on striatal dopamine D 2 -receptors. Neurology 44, 1325-1329.
3. Beekman, F.J., van der Have, F., Vastenhouw, B., van der Linden, A.J., van Rijk, P.P., Burbach, J.P., and Smidt, M.P. (2005). U-SPECT-I: a novel system for submillimeter-resolution tomography with radiolabeled molecules in mice. J. Nucl. Med. 46, 1194-1200. (Pubitemid 43741082)
4. Bernardi, M.M., De Souza, H., and Palermo Neto, J. (1981). Effects of single and long-term haloperidol administration on open field behavior of rats. Psychopharmacology (Berlin) 73, 171-175. (Pubitemid 11150294)
5. Björklund, L.M., Sanchez-Pernaute, R., Chung, S., Andersson, T., Chen, I.Y., McNaught, K.S., Brownell, A.L., Jenkins, B.G., Wahlestedt, C., Kim, K.S., and Isacson, O. (2002). Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc. Natl. Acad. Sci. USA 99, 2344-2349. (Pubitemid 34169063)
6. Bonatz, A.E., Steiner, H., and Huston, J.P. (1987). Video image analysis of behavior by microcomputer: categorization of turning and locomotion after 6-OHDA injection into the substantia nigra. J. Neurosci. Methods 22, 13-26. (Pubitemid 17146847)
7. Booij, J. and Knol, R.J. (2007). SPECT imaging of the dopaminergic system in (premotor) Parkinson's disease. Parkinonism Relat. Disord. 13 (Suppl. 3), S425-S428. (Pubitemid 351215280)
8. 123I] FP-CIT binds to the dopamine transporter as assessed by biodistribution studies in rats and SPECT studies in MPTP-lesioned monkeys. Synapse 27, 183-190. (Pubitemid 27430668)
9. 123Iodobenzamide single-photon emission tomography. Eur. J. Nucl. Med. 24, 674-677. (Pubitemid 27299750)
10. Booij, J., de Bruin, K., Habraken, J.B., and Voorn, P. (2002). Imaging of dopamine transporters in rats using high-resolution pinhole single-photon emission tomography. Eur. J. Nucl. Med. Mol. Imaging 29, 1221-1224. (Pubitemid 34985370)
11. 123I]FP-CIT binding to striatal dopamine transporters in rat brain: a validation study. Nucl. Med. Biol. 33, 409-411.
12. Brownell, A.L., Livni, E., Galpern, W., and Isacson, W. (1998). In vivo PET imaging in rat of dopamine terminals reveals functional neural transplants. Ann. Neurol. 43, 387-390. (Pubitemid 28113603)
13. Carboni, E. and Silvagni, A. (2004). Experimental investigations on dopamine transmission can provide clues on the mechanism of the therapeutic effect of amphetamine and methylphenidate in ADHD. Neural. Plast. 11, 77-95. (Pubitemid 39089573)
14. Chao, O.Y., Mattern, C., de Souza Silva, A.M., Weßler, J., Ruocco, L.A., Nikolaus, S., Huston, J.P., and Pum, M.E. (2011). Intranasally applied L-DOPA alleviates Parkinsonian symptoms in rats with unilateral nogro-striatal 6-OHDA lesions. Brain Res. Bull. (in press).
15. Chen, Y.C.I., Galpern, W.R., Brownell, A.L., Matthews, R.T., Bogdanov, M., Isacson, O., Keltner, J.R., Beal, M.F., Rosen, B.R., and Jenkins, B.G. (1997). Detection of dopaminergic neurotransmitter activity using pharmacologic MRI: correlation with PET, microdialysis, and behavioral data. Magn. Reson. Med. 38, 389-398. (Pubitemid 27386336)
16. Chen, Y.I., Brownell, A.L., Galpern, W., Isacson, O., Bogdanov, M., Beal, M.F., Livni, E., Rosen, B.R., and Jenkins, B.G. (1999). Detection of dopaminergic cell loss and neural transplantation using pharmacological MRI, PET and behavioral assessment. Neuroreport 10, 2881-2886. (Pubitemid 29507746)
17. Contin, M., Martinelli, P., Mochi, M., Albani, F., Riva, R., Scaglione, C., Dondi, M., Fanti, S., Pettinato, C., and Baruzzi, A. (2004). Dopamine transporter gene polymorphism, spect imaging, and levodopa response in patients with Parkinson disease. Clin. Neuropharmacol. 27, 111-115. (Pubitemid 38746009)
18. 125I] iodo- 2-methoxybenzamide hydrochloride, a new selective radioligand for dopamine D-2 receptors. J. Med. Chem. 31, 2027-1033.
19. De Souza Silva, M.A., Mattern, C., Häcker, R., Tomaz, C., Huston, J.P., and Schwarting, RK. (1997a). Increased neostriatal dopamine activity after intraperitoneal or intranasal administration of L-DOPA: on the role of benserazide pretreatment. Synapse 27, 294-302. (Pubitemid 27479467)
20. De Souza Silva, M.A., Mattern, C., Häcker, R., Nogueira, P.J., Huston, J.P., and Schwarting, R.K. (1997b). Intranasal administration of the dopaminergic agonists L-DOPA, amphetamine, and cocaine increases dopamine activity in the neostriatum: a microdialysis study in the rat. J. Neurochem. 68, 233-239. (Pubitemid 26427312)
21. Disselhorst, J.A., Brom, M., Laverman, P., Slump, C.H., Boerman, O.C., Oyen, W.J., Gotthardt, M., and Visser, E.P. (2010). Imagequality assessment for several positron emitters using the NEMA NU 4-2008 standards in the Siemens Inveon small-animal PET scanner. J. Nucl. Med. 51, 610-617.
22. 99mTc]TRODAT-1 to the central dopamine transporters in rats. Eur. J. Nucl. Med. 25, 31-93.
23. 99mTc]TRODAT-1 to the dopamine transporter before and after methylphenidate treatment. Eur. J. Nucl. Med. 27, 1518-1524.
24. Feifel, D. and Shilling, P.D. (2010). Promise and pitfalls of animal models of schizophrenia. Curr. Psychiatry Rep. 12, 327-334.
25. Ferr é, S. and Fuxe, K. (1992). Dopamine denervation leads to an increase in the intramembrane interactions between adenosine A 2 and dopamine D 2 receptors in the neostriatum. Brain Res. 595, 124-130.
26. Fink, J.S. and Smith, G.P. (1979). L-Dopa repairs deficits in locomotor and investigatory exploration produced by denervation of catecholamine terminal fields in the forebrain of rats. J. Comp. Physiol. Psychol. 93, 66-73. (Pubitemid 9140563)
27. Fornaguera, J., Schwarting, R.K., Boix, F., and Huston, J.P. (1993). Behavioral indices of moderate nigro-striatal 6-hydroxydopamine lesion: a preclinical Parkinson's model. Synapse 13, 179-185. (Pubitemid 23051485)
28. Fornaguera, J., Carey, R.J., Huston, J.P., and Schwarting, R.K. (1994). Behavioral asymmetries and recovery in rats with different degrees of unilateral striatal dopamine depletion. Brain Res. 664, 178-188. (Pubitemid 24347610)
29. Goorden, M.C. and Beekman, F.J. (2010). High-resolution tom ography of positron emitters with clustered pinhole SPECT. Phys. Med. Biol. 55, 1265-1277.
30. Grigoriadis, N., Simeonidou, C., Parashos, S.A., Alban, M., and Guiba- Tziampiri, O. (1996). Ontogenetic development of the locomotor response to levodopa in the rat. Pediatr. Neurol. 14, 41-45. (Pubitemid 26069530)
31. Guttman, M., Stewart, D., Hussey, D., Wilson, A., Houle, S., and Kish, S. (2001). Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD. Neurology 56, 1559-1564. (Pubitemid 32544560)
32. Hasenöhrl, R.U., Oitzl, M.S., and Huston, J.P. (1989). Conditioned place preference in the corral: a procedure for measuring reinforcing properties of drugs. J. Neurosci. Methods 30, 141-146. (Pubitemid 19255667)
33. Heikkila, R.E., Cabbat, F.S., Manzino, L., and Duvoisin, R.C. (1981). Potentiation by deprenil of 1-dopa induced circling in nigrallesioned rats. Pharmacol. Biochem. Behav. 15, 75-79. (Pubitemid 11083224)
34. Hommer, D.W. and Bunney, B.S. (1980). Effect of sensory stimuli on the activity of dopaminergic neurons: involvement of nondopaminergic nigral neurons and striato-nigral pathways. Life Sci. 27, 377-386. (Pubitemid 11227618)
35. Honer, M., Bruhlmeier, M., Missimer, J., Schubiger, A.P., and Ametamey, S.M. (2004). Dynamic imaging of striatal D2 receptors in mice using quad-HIDAC PET. J. Nucl. Med. 45, 464-470. (Pubitemid 47618622)
36. 11C]raclopride in anaesthetised rodents. Synapse 51, 206-212. (Pubitemid 38036954)
37. 11C]raclopride binding in rat striatum quantified using PET. Synapse 21, 45-53.
38. Hume, S.P., Gunn, R.N., and Jones, T. (1998). Pharmacological constraints associated with positron emission tomographic scanning of small laboratory animals. Eur. J. Nucl. Med. 25, 173-176. (Pubitemid 28130042)
39. Ichise, M., Kim, Y.J., Ballinger, J.R., Vines, D., Erami, S.S., Tanaka, F., and Lang, A.E. (1999). SPECT imaging of pre- and postsynaptic dopaminergic alterations in L-dopa-untreated PD. Neurology 52, 1206-1214. (Pubitemid 29177923)
40. Inaji, M., Okauchi, T., Ando, K., Maeda, J., Nagai, Y., Yoshizaki, T., Okano, H., Nariai, T., Ohno, K., Obayashi, S., et al. (2005). Correlation between quantitative imaging and behavior in unilaterally 6-OHDA-lesioned rats. Brain Res. 1064, 136-145. (Pubitemid 41774653)
41. 123I]IBZM binding to the D2 receptor in nonhuman primates. Synapse 10, 177-184.
42. Ishizu, K., Smith, D.F., Bender, D., Danielsen, E., Hansen, S.B., Wong, D.F., Cumming, P., and Gjedde, A. (2000). Positron emission tomography of radioligand binding in porcine striatum in vivo : haloperidol inhibition linked to endogenous ligand release. Synapse 38, 87-101. (Pubitemid 30659622)
43. 11C]raclopride binding. J. Cereb. Blood Flow Metab. 18, 941-950.
44. Jongen, C., de Bruin, K., Beekman, F., and Booij, J. (2008). SPECT imaging of D2 dopamine receptors and endogenous dopamine release in mice. Eur. J. Nucl. Med. Mol. Imaging 35, 1692-1698.
45. 11C]methylspiperone. J. Nucl. Med. 41, 65-70. (Pubitemid 30046685)
46. Kellogg, C., Lundborg, P., and Roos, B.E. (1972). Ontogenic changes in cerebral concentration of homovanillic acid in response to haloperidol treatment. Brain Res. 40, 469-475.
47. Koch, W., Hamann, C., Radau, P.E., and Tatsch, K. (2007). Does combined imaging of the pre- and postsynaptic dopaminergic system increase the diagnostic accuracy in the differential diagnosis of parkinsonism? Eur. J. Nucl. Med. Mol. Imaging 34, 1265-1273. (Pubitemid 47290664)
48. Kotian, P., Mascarella, S.W., Abraham, P., Lewin, A.H., Boja, J.W., Kuhar, M.J., and Carroll, F.I. (1996). Synthesis, ligand binding, and quantitative structure-activity relationship study of 3 β -(4′ - substituted phenyl)-2 β -heterocyclic tropanes: evidence for an electrostatic interaction at the 2 β -position. J. Med. Chem. 39, 2753-2763. (Pubitemid 26240344)
49. Krause, K.H., Dresel, S.H., Krause, J., Kung, H.F., and Tatsch, K. (2000). Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: effects of methylphenidate as measured by single photon emission computed tomography. Neurosci. Lett. 285, 107-110. (Pubitemid 30227631)
50. Krause, J., la Fougere, C., Krause, K.H., Ackenheil, M., and Dresel, S.H. (2005). Influence of striatal dopamine transporter availability on the response to methylphenidate in adult patients with ADHD. Eur. Arch. Psychiatry Clin. Neurosci. 255, 428-431. (Pubitemid 43029831)
51. Kugaya, A., Fujita, M., and Innis, R.B. (2000). Applications of SPECT imaging of dopaminergic neurotransmission in neuropsychiatric disorders. Ann. Nucl. Med. 14, 1-9. (Pubitemid 30190873)
52. Lammertsma, A.A. and Hume, S.P. (1996). Simplified reference tissue model for PET receptor studies. Neuroimage 4, 153-158.
53. Larisch, R. and Klimke, A. (1998). Clinical impact of cerebral dopamine- D2 receptor scintigraphy. Nucl.Med. 37, 245-250. (Pubitemid 28525303)
54. 123I]beta-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse 13, 295-309. (Pubitemid 23104535)
55. Laruelle M. (2000). Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J. Cereb. Blood Flow Metab. 20, 423-451. (Pubitemid 30164887)
56. Lee, F.J., Pristupa, Z.B., Ciliax, B.J., Levey, A.I., and Niznik, H.B. (1996). The dopamine transporter carboxyl-terminal tail. Truncation/substitution mutants selectively confer high affinity dopamine uptake while attenuating recognition of the ligand binding domain. J. Biol. Chem. 271, 20885-20894. (Pubitemid 26281877)
57. Lindgren, H.S., Andersson, D.R., Lagerkvist, S., Nissbrandt, H., and Cenci, M.A. (2010). L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia. J. Neurochem. 112, 1465-1476.
58. Lipska, B.K. (2004). Using animal models to test a neurodevelopmental hypothesis of schizophrenia. J. Psychiat. Neurosci. 29, 282-286. (Pubitemid 39179574)
59. 11C]N- methylspiperone dopamine D2 receptor binding after chronic binge cocaine: a positron emission tomography study in rats. Neuropsychopharmacology 19, 146-153. (Pubitemid 28288440)
60. Matecka, D., Rothman, R.B., Radesca, L., de Costa, B.R., Dersch, C.M., Partilla, J.S., Pert, A., Glowa, J.R., Wojnicki, F.H., and Rice, K.C. (1996). Development of novel, potent, and selective dopamine reuptake inhibitors through alteration of the piperazine ring of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl) methoxy]ethyl]-4-(3-phenylpropyl) piperazines (GBR 12935 and GBR 12909). J. Med. Chem. 39, 4704-4716.
61. McDevitt, J.T. and Setler, P.E. (1981). Differential effects of dopamine agonists in mature and immature rats. Eur. J. Pharmacol. 72, 69-75. (Pubitemid 11123278)
62. Mehler-Wex, C., Riederer, P., and Gerlach, M. (2006). Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson's disease, schizophrenia and attention deficit hyperactivity disorder. Neurotox. Res. 10, 167-179.
63. Meyer, P.T., Salber, D., Schiefer, J., Cremer, M., Schaefer, W.M., Kosinski, C.M., and Langen, K.J. (2008). Cerebral kinetics of the dopamine D 2 receptor ligand [(123)I]IBZM in mice. Nucl. Med. Biol. 35, 467-473.
64. Moghaddam, R. and Bunney, B.J. (1990). Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J. Neurochem. 54, 1755-1760.
65. Morgan, S., Nomikos, G., and Huston, J.P. (1993). Behavioral analysis of asymmetries induced by unilateral 6-OHDA injections into the substantia nigra. Behav. Neural Biol. 60, 241-250. (Pubitemid 24004192)
66. Morris, R. (1984). Developments of a water-maze procedure for studying spatial learning in the rat. J. Neurosci. Methods 11, 47-60. (Pubitemid 14088970)
67. Mura, A., Jackson, D., Manley, M.S., Young, S.J., and Groves, P.M. (1995). Aromatic L-amino acid decarboxylase immunoreactive cells in the rat striatum: a possible site for the conversion of exogenous L-DOPA to dopamine. Brain Res. 704, 51-60. (Pubitemid 3013614)
68. Nakazato, T. and Akiyama, A. (1989). Effect of exogenous L-dopa on behavior in the rat: an in vivo voltammetric study. Brain Res. 490, 332-338. (Pubitemid 19158565)
69. Navarrete, R., Slawi ska, U., and Vrbová, G. (2002). Electromyographic activity patterns of ankle flexor and extensor muscles during spontaneous and L-DOPA-induced locomotion in freely moving neonatal rats. Exp. Neurol. 173, 256-265. (Pubitemid 34151377)
70. Neumeyer, J.L., Wang, S., Gao, Y., Kula, N.S., Campbell, A., Baldessarini, R.J., Zea-Ponce, Y., Baldwin, R.M., and Innis, R.B. (1994). N-omega-fluoroalkyl analogs of (1R)-2β-carbomethoxy- 3β-(4-iodophenyl) -tropane (β-CIT): radiotracers for positron emission tomography and single photon emission computed tomography imaging of dopamine transporters. J. Med. Chem. 37, 1558-1561. (Pubitemid 24195468)
71. Neve, K.A., Kozlowski, M.R., and Marshall, J.F. (1982). Plasticity of neostriatal dopamine receptors after nigrostriatal injury: relationship to recovery of sensorimotor functions and behavioral supersensitivity. Brain Res. 244, 33-44. (Pubitemid 12095245)
72. 3H]spiroperidol binding to rat forebrain sections: plasticity of neostriatal dopamine receptors after nigrostriatal injury. Brain Res. 302, 9-18. (Pubitemid 14095407)
73. Nguyen, T.V., Brownell, A.L., Chen, Y.C.I., Livni, E., Coyle, J.T., Rosen, B.R., Cavagna, F., and Jenkins, B.G. (2000). Detection of the effects of dopamine receptor sensitivity using pharmacological MRI and correlations with PET. Synapse 36, 57-65. (Pubitemid 30134125)
74. Nikolaus, S., Huston, J.P., Körber, B., Thiel, C., and Schwarting, R.K.W. (1997). Pretreatment with neurokinin substance P but not with cholecystokinin-8S can alleviate functional deficits of partial nigrostriatal 6-hydroxydopamine lesion. Peptides 18, 1161-1168. (Pubitemid 28026884)
75. Nikolaus, S., Huston, J.P., and Schwarting, R.K.W. (1999). Pretreatment with fragments of substance-P or with cholecystokinin differentially affects recovery from subtotal nigrostriatal 6-hydroxydopamine lesion. Neural Plast. 6, 77-89. (Pubitemid 29516384)
76. 18F] N-methyl-benperidol. J. Nucl. Med. 42, 1691-1696. (Pubitemid 33131331)
77. Nikolaus, S., Larisch, R., Beu, M., Vosberg, H., and Müller- Gärtner, H.W. (2003a). Bilateral increase of striatal dopamine D 2 receptor density in the 6-hydroxydopamine-lesioned rat: a serial in vivo investigation with small animal positron emission tomography. Eur. J. Nucl. Med. Mol. Imaging 30, 390-395. (Pubitemid 36692864)
78. 18F](3-N-methyl)benperidol in the rat striatum with a PET system for small laboratory animals. J. Nucl. Med. 44, 18-24.
79. Nikolaus, S., Beu, M., Vosberg, H., Müller, H.W., and Larisch, R. (2004a). Quantitative analysis of dopamine D 2 receptor kinetics with small animal positron emission tomography. Meth. Enzymol. 385, 228-239. (Pubitemid 38656330)
80. Nikolaus, S., Beu, M., Wirrwar, A., Vosberg, H., Müller, H.W., and Larisch, R. (2004b). The contribution of small animal positron emission tomography to the neurosciences-a critical evaluation. Rev. Neurosci. 15, 131-156. (Pubitemid 38858894)
81. 123I]FP-CIT and a dedicated small animal SPECT. Eur. J. Nucl. Med. Mol. Imaging 32, 308-315.
82. 2 receptor in competition with haloperidol and endogenous dopamine - an in vivo imaging study with a dedicated small animal SPECT. Eur. J. Nucl. Med. Mol. Imaging 32, 1305-1310. (Pubitemid 41598722)
83. Nikolaus, S., Beu, M., Wirrwar, A., Antke, C., and Müller, H.W. (2005c). In vivo snapshots of the dopaminergic synapse in small animals. Mol. Psychiat. 10, 516-518. (Pubitemid 40897032)
84. Nikolaus, S., Antke, C., Kley, K., Poeppel, T.D., Hautzel, H., Schmidt, D., and Müller, H.W. (2007a). Investigating the dopaminergic synapse in vivo. I. Molecular imaging studies in humans. Rev. Neurosci. 18, 439-472. (Pubitemid 351184054)
85. Nikolaus, S., Antke, C., Kley, K., Poeppel, T.D., Hautzel, H., Schmidt, D., and Müller, H.W. (2007b). Investigating the dopaminergic synapse in vivo. II. Molecular imaging studies in small laboratory animals. Rev. Neurosci. 18, 473-504. (Pubitemid 351184055)
86. Nikolaus, S., Wirrwar, A., Kley, K., Antke, C., and Müller, H.W. (2007c). In vivo quantification of dose-dependendent dopamine transporter blockade in the rat striatum with small animal SPECT. Nucl. Med. Commun. 28, 207-213. (Pubitemid 46192956)
87. Nikolaus, S., Antke, C., and Müller, H.W. (2009a). In vivo imaging of synaptic function in the central nervous system. I. Movement disorders and dementia. Behav. Brain Res. 204, 1-31.
88. Nikolaus, S., Antke, C., and Müller, H.W. (2009b). In vivo imaging of synaptic function in the central nervous system. II. Mental and affective disorders. Behav. Brain Res. 204, 32-66.
89. 123I] FP-CIT binding to the dopamine transporter in the rat striatum-an in vivo imaging study with a dedicated small animal SPECT. J. Nucl. Med. 50, 1147-1152.
90. 18F]N-methyl-benperidol. Open Nucl. Med. J. 1, 25-32.
91. Nikolaus, S., Beu, M., Antke, C., and Müller, H.W. (2010). Cortical GABA, striatal dopamine and midbrain serotonin as the key players in compulsive and anxiety disorders-Results from in vivo imaging studies. Rev. Neurosci. 21, 119-139.
92. Nikolaus, S., Larisch, R., Vosberg, H., Beu, M., Wirrwar, A., Hautzel, H., Müller, H.W., and Antke, C. (2011a). In vivo imagaing neurotransmitter function in the rat 6-hydroxydopamine model and the relevance of findings for human Parkinson's disease. Nucl. Med. 50, 155-166.
93. 123I]iodobenzamide to the rat D 2 receptor after challenge with methylphenidate assessed with a dedicated small animal SPECT. Eur. J. Nucl. Med. Mol. Imaging 38, 694-701.
94. Ogren, S.O., Rodebjer, A., and Angeby, K. (1984). The'presynaptic'blocking potency of sulpiride and haloperidol in the rat is agedependent. Neurosci. Lett. 46, 203-207. (Pubitemid 14147491)
95. Olds, J. and Milner, P. (1954). Positive reinforcement produced by electrical stimulation of septal area and other regions of rat brain. J. Comp. Physiol. Psychol. 47, 419-427.
96. Olton, D.S. and Samuelson, R.J. (1976). Remembrance of places passed: Spatial memory in rats. J. Exp. Psychol. Anim. Behav. Process. 2, 97-116.
97. Opacka-Juffry, J., Ashworth, S., Hume, S.P., Martin, D., Brooks, D.J., and Blunt, S.B. (1995). GDNF protects against 6-hydroxydopamine lesion: in vivo study with microdialysis and PET. Neuroreport 7, 348-352. (Pubitemid 26078187)
98. Parkinson Study Group. (2002). Dopamine transporter brain imaging to assess the effects of pramipexole vs. Levodopa on Parkinson's disease progression. JAMA 287, 1653-1661.
99. Parkinson Study Group. (2004). Levodopa and the progression of Parkinson's disease. N. Engl. J. Med. 46, 2498-2508.
100. Paxinos, G. and Watson, C. (1986). The rat brain in stereotaxic coordinates. (Sydney, Australia: Academic Press).
101. Pehek, E.A. and Yamamoto, B.K. (1994). Differential effects of locally administered clozapine and haloperidol on dopamine efflux in the rat prefrontal cortex and caudate-putamen. J. Neurochem. 63, 2118-2124. (Pubitemid 24369986)
102. Pehek, E.A. (1999). Comparison of effects of haloperidol administration on amphetamine-stimulated dopamine release in the rat medial prefrontal cortex and dorsal striatum. J. Pharmacol. Exp. Ther. 289, 14-23. (Pubitemid 29156007)
103. Pellow, S., Chopin, P., File, S.E., and Briley, M. (1985). Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods 14, 149-167. (Pubitemid 16239568)
104. Pezzoli, G. and Zini, M. (2010). Levodopa in Parkinson's disease: from the past to the future. Expert. Opin. Pharmacother. 11, 627-635.
105. 123Ilabelled probes. Eur. J. Nucl. Med. Mol. Imaging 36, 1495-1509.
106. Poewe, W. and Scherfler, C. (2003). Role of dopamine transporter imaging in investigation of parkinsonian syndromes in routine clinical practice. Mov. Disord. 18 (Suppl. 7), S16-S21. (Pubitemid 37336923)
107. Pritzel, M. and Huston, J.P. (1981). Unilateral ablation of telencephalon induces appearance contralateral cortical and subcortical projections to thalamic nuclei. Behav. Brain. Res. 3, 43-54. (Pubitemid 11117775)
108. Pritzel, M., Huston, J.P., and Sarter, M. (1983). Behavioral and neuronal reorganization after unilateral substantia nigra lesions: evidence for increased interhemispheric nigrostriatal projections. Neuroscience 9, 879-888. (Pubitemid 13039170)
109. 123I]FP- CIT binding to dopamine transporters in rat frontal cortex and hippocampus. Synapse 39, 193-200. (Pubitemid 32099674)
110. Rosa-Neto, P., Lou, H.C., Cumming, P., Pryds, O., Karrebaek, H., Lunding, J., and Gjedde, A. (2005). Methylphenidate-evoked changes in striatal dopamine correlate with inattention and impulsivity in adolescents with attention deficit hyperactivity disorder. Neuroimage 25, 868-876. (Pubitemid 40461725)
111. Russell, V.A., Sagvolden, T., and Johansen, E.B. (2005). Animal models of attention-deficit hyperactivity disorder. Behav. Brain. Funct. 15, 1-9.
112. Saji, H., Iida, Y., Kawashima, H., Ogawa, M., Kitamura, Y., Mukai, T., Shimazu, S., and Yoneda, F. (2003). In vivo imaging of brain dopaminergic neurotransmission system in small animals with high-resolution single photon emission computed tomography. Anal. Sci. 19, 67-71.
113. 2 receptor status. Brain 116, 853-867. (Pubitemid 23242811)
114. 123I]IBZM pinhole SPECT for the detection of striatal dopamine D 2 receptor availability in rats. Neuroimage 24, 822-831. (Pubitemid 40094564)
115. Schiffer, W.K., Volkow, N.D., Fowler, J.S., Alexoff, D.L., Logan, J., and Dewey, S.L. (2006). Therapeutic doses of amphetamine or methylphenidate differentially increase synaptic and extracellular dopamine. Synapse 59, 243-251. (Pubitemid 43202592)
116. 123I-FP-CIT in patients with parkinson's disease. Eur. J. Nucl. Med. Mol. Imaging 32, 1452-1456. (Pubitemid 41746850)
117. Schramm, N., Wirrwar, A., Sonnenberg, F., and Halling, H. (2000). Compact high resolution detector for small animal SPECT. IEEE Trans. Nucl. Sci. 47, 1163-1166.
118. Schramm, N.U., Ebel, G., Engeland, U., Schurrat, T., Béhé, M., and Behr, T.M. (2003). High-resolution SPECT using multipinhole collimation. IEEE Trans. Nucl. Sci. 50, 315-320.
119. Schulz, D., Southekal, S., Junnarkar, S.S., Pratte, J.F., Purschke, M.L., Stoll, S.P., Ravindranath, B., Maramraju, S.H., Krishnamoorthy, S., Henn, F.A., et al. (2011). Simultaneous assessment of rodent behavior and neurochemistry using a miniature positron emission tomograph. Nat. Methods 4, 347-352.
120. Schwarting, R.K.W. and Huston, J.P. (1996a). Unilateral 6-hydroxydopamine lesions of meso-striatal dopamine neurons and their physiological sequelae. Prog. Neurobiol. 49, 215-266. (Pubitemid 26276331)
121. Schwarting, R.K.W. and Huston, J.P. (1996b). The unilateral 6- hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog. Neurobiol. 50, 275-331. (Pubitemid 26412599)
122. Schwarting, R.K., Bonatz, A.E., Carey, R.J., and Huston, J.P. (1991). Relationships between indices of behavioral asymmetries and neurochemical changes following mesencephalic 6-hydroxydopamine injections. Brain Res. 554, 46-55.
123. Seeman, P. and Grigoriadis, D. (1987). Dopamine receptors in brain and periphery. Neurochem. Int. 10, 1-25. (Pubitemid 17012054)
124. Seeman, P. and Madras, B. (2002). Methylphenidate elevates resting dopamine which lowers the impulse-triggered release of dopamine: a hypothesis. Behav. Brain Res. 130, 79-83. (Pubitemid 34195323)
125. Seibyl, J.P., Woods, S.W., Zoghbi, S.S., Baldwin, R.M., Dey, H.M., Goddard, A.W., Zea-Ponce, Y., Zubal, G., Germine, M., Smith, E.O., et al. (1992). Dynamic SPECT imaging of dopamine D 2 receptors in human subjects with iodine-123-IBZM. J. Nucl. Med. 33, 1964-1971.
126. Shen, H., Kannari, K., Yamato, H., Arai, A., and Matsunaga, M. (2003). Effects of benserazide on L-DOPA-derived extracellular dopamine levels and aromatic L-amino acid decarboxylase activity in the striatum of 6-hydroxydopamine-lesioned rats. Tohoku J. Exp. Med. 199, 149-159. (Pubitemid 36519467)
127. Sossi, V., Dinelle, K., Schulzer, M., Mak, E., Doudet, D.J., and de la Fuente-Fernandez, R. (2010). Levodopa and pramipexole effects on presynaptic dopamine PET markers and estimated dopamine release. Eur. J. Nucl. Med. Mol. Imaging 37, 2364-2370.
128. Staubli, U. and Huston, J.P. (1979). Up-hill avoidance: a new passive- avoidance task. Physiol. Behav. 22, 775-776. (Pubitemid 9194053)
129. Staunton, D.A., Wolfe, B.B., Groves, P.M., and Molinoff, P.B. (1981). Dopamine receptor changes following destruction of the nigrostriatal pathway: lack of a relationship to rotational behavior. Brain Res. 211, 315-327. (Pubitemid 11150825)
130. Steiner, H., Morgan, S., and Huston, J.P. (1985). Effect of forebrain commissurotomy on recovery from unilateral 6-OHDA lesions of the substantia nigra and circling induced by apomorphine. Behav. Brain Res. 17, 245-249. (Pubitemid 16192774)
131. Steiner, H., Bonatz, A.E., Huston, J.P., and Schwarting, R. (1988). Lateralized wall-facing versus turning as measures of behavioral asymmetries and recovery of function after injection of 6-hydroxydopamine into the substantia nigra. Exp. Neurol. 99, 5565-5566.
132. Strome, E.M., Cepeda, I.L., Sossi, V., and Doudet, D.J. (2006). Evaluation of the integrity of the dopamine system in a rodent model of Parkinson's disease: small animal positron emission tomography compared to behavioral assessment and autoradiography. Mol. Imaging Biol. 8, 292-299. (Pubitemid 44446023)
133. Strömbom, U. (1977). Antagonism by haloperidol of locomotor depression induced by small doses of apomorphine. J. Neural Transm. 40, 191-194. (Pubitemid 8086061)
134. Suehiro, M., Dannals, R.F., Scheffel, U., Stathis, M., Wilson, A.A., and Ravert, H.T. (1990). Villemagne VL, Sanchez-Roa PM, Wagner HN Jr. In vivo labelling of the dopamine D2 receptor with N-11C-methyl-benperidol. J. Nucl. Med. 31, 2015-2021.
135. Swanson, J.M., Cantwell, D., Lerner, M., McBurnett, K., and Hanna, G. (1991). Effects of stimulant medication on learning in children with ADHD. J. Learn. Disabil. 24, 219-230.
136. Tai, Y.C., Ruangma, A., Rowland, D., Siegel, S., Newport, D.F., Chow, P.L., and Laforest, R. (2005). Performance evaluation of the microPET focus: a third-generation microPET scanner dedicated to animal imaging. J. Nucl. Med. 46, 455-463. (Pubitemid 43093155)
137. Tatsch, K. (2010). Extrapyramidal syndromes: PET and SPECT. Neuroimaging Clin. N. Am. 20, 57-68.
138. Thomas, J., Wang, J., Takubo, H., Sheng, J., de Jesus, S., and Bankiewicz, K.S. (1994). A 6-hydroxydopamine-induced selective parkinsonian rat model: further biochemical and behavioral characterization. Exp. Neurol. 126, 159-167.
139. 2 receptors in the rat brain: an in vivo study using positron emission tomography. J. Neurosci. 16, 7670-7677. (Pubitemid 26389706)
140. Ungerstedt, U. (1971). Postsynaptic supersensitivity after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol. Scand., 367 (Supp l.), 69-93.
141. Unterwald, E.M., Tsukada, H., Kakiuchi, T., Kosugi, T., Nishiyama, S., and Kreek, M.J. (1997). Use of positron emission tomography to measure the effects of nalmefene on D 1 and D 2 dopamine receptors in rat brain. Brain Res. 775, 183-188. (Pubitemid 28020502)
142. Van Hartesveldt, C., Sickles, A.E., Porter, J.D., and Stehouwer, D.J. (1991). L-dopa-induced air-stepping in developing rats. Brain Res. Dev. Brain Res. 58, 251-255.
143. 123I]IBZM) in rat and human brain. Int. J. Rad. Appl. Instrum. B 18, 837-846.
144. Viggiano, D., Vallone, D., and Sadile, A. (2004). Dysfunctions in dopamine systems and ADHD: evidence from animals and modeling. Neural Plast. 11, 97-114. (Pubitemid 39089574)
145. Volkow, N.D., Wang, G.J., Fowler, J.S., Gatley, S.J., Logan, J., Ding, Y.S., Hitzemann, R., and Pappas, N. (1998). Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am. J. Psychiatry 155, 1325-1331. (Pubitemid 28471187)
146. Volkow, N.D., Wang, G.J., Fowler, J.S., Logan, J., Gatley, S.J., Wong, C., Hitzemann, R., and Pappas, N.R. (1999a). Reinforcing effects of psychostimulants in humans are associated with increases in brain dopamine and occupancy of D2 receptors. J. Pharmacol. Exp. Ther. 291, 409-415. (Pubitemid 29451617)
147. Volkow, N.D., Fowler, J.S., Gatley, S.J., Dewey, S.L., Wang, G.J., Logan, J., Ding, Y.S., Franceschi, D., Gifford, A., Morgan, A., et al. (1999b). Comparable changes in synaptic dopamine induced by methylphenidate and by cocaine in the baboon brain. Synapse 31, 59-66. (Pubitemid 29009280)
148. Volkow, N.D., Wang, G.J., Fowler, J.S., Logan, J., Gerasimov, M., Maynard, L., Ding, Y., Gatley, S.J., Gifford, A., and Franceschi, D. (2001). Therapeutic doses of oral methylphenidate signifi cantly increase extracellular dopamine in the human brain. J. Neurosci. 21, RC121.
149. Volkow, N.D., Wang, G.J., Fowler, J.S., Logan, J., Franceschi, D., Maynard, L., Ding, Y.S., Gatley, S.J., Gifford, A., Zhu, W., et al. (2002a). Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications. Synapse 43, 181-187. (Pubitemid 34087672)
150. Volkow, N.D., Fowler, J.S., Wang, G., Ding, Y., and Gatley, S.J. (2002b). Mechanism of action of methylphenidate: insights from PET imaging studies. J. Atten. Disord. 6 (Suppl. 1), 31-43.
151. Volkow, N.D., Wang, G.J., Fowler, J.S., and Ding, Y.S. (2005). Imaging the effects of methylphenidate on brain dopamine: new model onits therapeutic action for attention-deficit/hyperactivity disorder. Biol. Psychiat. 57, 1410-1415. (Pubitemid 40798562)
152. Weber, S., Terstegge, A., Herzog, H., Reinartz, R., Reinhart, P., Rongen, F., Müller-Gärtner, H.W., and Halling, H. (1997). The design of an animal PET: flexible geometry for achieving optimal spatial resolution or high sensitivity. IEEE Trans. Med. Imaging 16, 684-698.
153. Weisenberger, A.G., Kross, B., Majewski, S., McKisson, J., Popov, V., Proffitt, J., Stolin, A., Baba, J.S., Goddard, J.S., Lee, S.J., et al. (2008). Awake animal SPECT: overview and initial results. IEEE Nuclear Science Symposium Conference Record 5588-5591.
154. Westerink, B.H.C. and de Vries, J.B. (1989). On the mechanism of neuroleptic induced increase in striatal dopamine release: brain dialysis provides direct evidence for mediation by autoreceptors on nerve terminals. Neurosci. Lett. 99, 197-202. (Pubitemid 19098462)
155. Willner, P. (1984). The validity of animal models of depression. Psychopharmacology (Berlin) 83, 1-16. (Pubitemid 14141479)
156. Wirrwar, A.K., Nikolaus, S., Schramm, N.U., Arkian, S., Cohnen, M., and Müller, H.W. (2005). TierSPECT: Performance parameters of a dedicated small animal SPECT camera and first in vivo measurements. Z. Med. Phys. 15, 14-22. (Pubitemid 40460413)
157. Wu, Q., Reith, M.E., Walker, Q.D., Kuhn, C.M., Carroll, F.I., and Garris, P.A. (2002). Concurrent autoreceptor-mediated control of dopamine release and uptake during neurotransmission: an in vivo voltammetric study. J. Neurosci. 22, 6272-6281. (Pubitemid 35387668)
158. Yang, P.B., Swann, A.C., and Dafny, N. (2006). Dose-response characteristics of methylphenidate on locomotor behavior and on sensory evoked potentials recorded from the VTA, NAc, and PFC in freely behaving rats. Behav. Brain Funct. 2, 3.